

# Robert J Kerns

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/177581/robert-j-kerns-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

2,049  
citations

17  
h-index

38  
g-index

38  
ext. papers

2,433  
ext. citations

5.4  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
37	Small molecule SWELL1 complex induction improves glycemic control and nonalcoholic fatty liver disease in murine Type 2 diabetes.. <i>Nature Communications</i> , <b>2022</b> , 13, 784	17.4	1
36	Suppression of human T cell activation by derivatives of glycerol monolaurate. <i>Scientific Reports</i> , <b>2021</b> , 11, 8943	4.9	1
35	A Novel Triphenylphosphonium Carrier to Target Mitochondria without Uncoupling Oxidative Phosphorylation. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 662-676	8.3	14
34	Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model. <i>Free Radical Research</i> , <b>2020</b> , 54, 311-318	4	11
33	Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase. <i>Bioorganic and Medicinal Chemistry</i> , <b>2020</b> , 28, 115439	3.4	2
32	Probing structural requirements for human topoisomerase I inhibition by a novel N1-Biphenyl fluoroquinolone. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 172, 109-130	6.8	5
31	Fluoroquinolone Resistance <b>2019</b> , 125-161		2
30	The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone. <i>Biochimie</i> , <b>2019</b> , 160, 24-27	4.6	4
29	Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 378-383	4.3	2
28	Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2018</b> , 28, 1903-1910	2.9	13
27	Effect of a mitochondrial-targeted coenzyme Q analog on pancreatic $\beta$ cell function and energetics in high fat fed obese mice. <i>Pharmacology Research and Perspectives</i> , <b>2018</b> , 6, e00393	3.1	20
26	Bacterial Type II Topoisomerases and Target-Mediated Drug Resistance <b>2018</b> , 507-529		8
25	Metabolic effects of a mitochondrial-targeted coenzyme Q analog in high fat fed obese mice. <i>Pharmacology Research and Perspectives</i> , <b>2017</b> , 5, e00301	3.1	17
24	Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance. <i>Biochemistry</i> , <b>2017</b> , 56, 4191-4200	3.2	10
23	Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 3304-16	20.1	16
22	Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 1706-13	11.5	112
21	Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E839-46	11.5	56

20	N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3. <i>Glycobiology</i> , <b>2016</b> , 26, 701-709	5.8	17
19	Fluoroquinolones stimulate the DNA cleavage activity of topoisomerase IV by promoting the binding of Mg(2+) to the second metal binding site. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2016</b> , 1860, 569-75	4	4
18	Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions. <i>Biochemistry</i> , <b>2015</b> , 54, 1278-86	3.2	18
17	A mitochondrial-targeted coenzyme q analog prevents weight gain and ameliorates hepatic dysfunction in high-fat-fed mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 351, 699-708	4.7	30
16	Bypassing fluoroquinolone resistance with quinazolinones: studies of drug-gyrase-DNA complexes having implications for drug design. <i>ACS Chemical Biology</i> , <b>2014</b> , 9, 2895-904	4.9	33
15	Mechanism of quinolone action and resistance. <i>Biochemistry</i> , <b>2014</b> , 53, 1565-74	3.2	632
14	Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. <i>Biochemistry</i> , <b>2014</b> , 53, 5558-67	3.2	32
13	Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3227-35	5.1	21
12	Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7182-7	5.9	8
11	Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. <i>ACS Chemical Biology</i> , <b>2013</b> , 8, 2660-8	4.9	50
10	Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 4628-39	20.1	97
9	Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. <i>Biochemistry</i> , <b>2012</b> , 51, 370-81	3.2	61
8	Synthetic Methods To Incorporate Linked 2-Amino-2-Deoxy-D-Glucopyranoside and 2-Amino-2-Deoxy-D-Galactopyranoside Residues into Glycoconjugate Structures. <i>ACS Symposium Series</i> , <b>2012</b> , 235-263	0.4	5
7	Quinolones: action and resistance updated. <i>Current Topics in Medicinal Chemistry</i> , <b>2009</b> , 9, 981-98	3	236
6	Quinolone-mediated bacterial death. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 385-92	5.9	374
5	Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2006</b> , 54, 305-10	2.9	9
4	Synthetic Methods to Incorporate Linked 2-Amino-2-Deoxy-D-Glucopyranoside and 2-Amino-2-Deoxy-D-Galactopyranoside Residues into Glycoconjugate Structures. <i>ACS Symposium Series</i> , <b>2006</b> , 205-236	0.4	4
3	Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 2109-12	2.9	69

2	Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 1745-9	2.9	48
1	Selective N-Sulfation of Glucosamine Derivatives using Phenyl Chlorosulfate in Non-Aqueous Solvent. <i>Synthetic Communications</i> , <b>1996</b> , 26, 2671-2680	1.7	5